SGLT2 Inhibitors

Sodium-glucose cotransporter 2 (SGLT2) is a membrane protein expressed in the proximal tubules of the kidney which plays a key role in the reabsorption of glucose from the urine. Dapagliflozin (1) and ipragliflozin (2) are inhibitors of SGLT2 and promote urinary glucose excretion and subsequent blood glucose level modulation.¹⁾ The combination of SGLT2 inhibitors with insulin has been reported to improve HbA1c* levels while reducing the risk of hypoglycemia, making these compounds valuable tools in cardio-renal research.²⁾
In recent years, SGLT2 inhibitors have also gained attention in cardiovascular studies, particularly in heart failure research. They are thought to alleviate cardiac burden by reducing afterload through vasodilation and decreasing preload through diuresis, potentially improving cardiac function and slowing disease progression.³⁾
(These products are for research purpose only.)

*HbA1c : Hemoglobin A1c (HbA1c) test is used to gauge average long-term (1-2 months) blood glucose levels, performed by measuring the degree of binding of glucose to hemoglobin in red blood cells.

References

• 1) Renal effects of SGLT2 inhibitors: an update
  • J. Nespoux, V. Vallon, Curr. Opin. Nephrol. Hypertens. 2020, 29, 190.
• 2) Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials
  • Y. Yang, S. Chen, H. Pan, Y. Zou, B. Wang, G. Wang, H. Zhu, Medicine 2017, 96, e6944.
• 3) Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
  • F. Yang, R. Meng, D.-L. Zhu, Chronic Dis. Transl. Med. 2020, 6, 239.

Related Products

I1257

Insulin solution (4mg/mL) [Optimized for Cell Culture]

G0656

Glucose Measurement Kit

Page Top